



**Javier Cortés, MD PhD**

**Head, International Breast Cancer Center (IBCC), Barcelona, Spain**

**Clinical Investigator, Breast Cancer Research Program  
Vall d'Hebron Institute of Oncology, Barcelona, Spain**

Dr. Javier Cortés received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996, specialist in Medical Oncology by the Clínica Universitaria de Navarra, and awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. From June 2003 to July 2015, he has worked in the Department of Medical Oncology at the Hospital Vall d'Hebron, Barcelona, where he has been Coordinator of the Teaching and Training Programme for Residents in Oncology. In addition he was the Head of the Breast Cancer Program from July 2006 to August 2015. From September 2015 to October 2018, he has been Head of the Breast Cancer and Gynecological tumors at Ramon y Cajal University Hospital in Madrid. Dr. Cortés was the Head of the Breast Cancer Program at IOB Institute of Oncology, Quironsalud group, in both Madrid and Barcelona, from 2011 to September 2020.

Actually, Dr. Cortés is the Head of the International Breast Cancer Centre (IBCC) in Barcelona, founding partner of Medica Scientia innovation Research (MedSIR), a company involved in the clinical development of clinical trials, and Senior Clinical Investigator of the Breast Cancer Research Program at Vall d'Hebron Institute of Oncology.

In addition to his medical specialties, he has two master degrees in “Medical Direction and Clinical Management” by the *Universidad Nacional de Educación a Distancia (UNED)* and “Research methodology in Health Sciences” by the *Universidad Autónoma de Barcelona* and a degree in “Statistics in Health Sciences” by the *Universidad Autónoma de Barcelona*.

He is the author of more than 300 publications, especially about breast tumours and new drugs and more than 600 communications at different conferences. He actively participates in the development of numerous international clinical trials, and he is an ad hoc reviewer of various oncology journals, including, New England Journal of Medicine, Lancet, Lancet Oncology, Annals of Oncology or Journal of Clinical Oncology, among many others

Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO). In addition, he is a member of the Scientific Committee of the European Society of Medical Oncology (ESMO), Chair of the Committee for Breast Cancer, local therapy, ESMO 2020 and Co-Chair of the American Association for Cancer research (AACR) Annual Meeting 2021 Program Committee.

17 JUL 2021

### Top 10 publications over the last 3 years:

- Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdžic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, Hadfield J, Eldridge M, McLaren-Douglas A, Barthorpe A, Lightfoot H, O'Connor MJ, Gray J, Cortes J, Baselga J, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas C. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. **Cell**. 2016 Sep 22;167(1):260-274.
- Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A.; HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. **Lancet Oncol**. 2017 Apr;18(4):545-554.
- Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. **Lancet Oncol**. 2017 Jul;18(7):904-916.
- Méndez-Pertuz M, Martiñez P, Blanco-Aparicio C, Gómez-Casero E, García AB, Martínez-Torre Cuadrada J, Palafox M, Cortés J, Serra V, Pastor J, Blasco MA. Modulation of telomere protection by the PI3K/AKT pathway. **Nat Commun** 2017 Nov 2;8(1):1278.
- Perez García J, Cortes J. Breast cancer in 2017: Spurring science, marking progress, and influencing history. **Nat Rev Clin Oncol**. 2018 Feb;15(2):79-80.
- Cortes J, Perez-Garcia J, Levy C, Gómez Pardo P, Bourgeois H, Spazzapan S, Martínez-Jañez N, Chao T, Espié M, Nabholtz JM, González Farré X, Beliakouski V, Román García J,

Holgado E, Campone M. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer. **Ann Oncol**. 2018. 29(4) 881-887.

- Pernas S, Martin M, A. Kaufman P, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, O. Ademuyiwa F, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia P, Wach A, Barker D, Fung S, Romagnoli B, **Cortes J**. The CXCR4 antagonist, balixafortide, plus eribulin in HER2-negative metastatic breast cancer: a Phase I, open-label, single-arm trial. **Lancet Oncol** 2018 Jun;19(6):812-824
- Rugo HS, **Cortes J**, Awada A, O'Shaughnessey Joyce, Twelves CJ, Im S, Hannah A, Lu L, Sy S, Caygill K, Zajchowski D, W. Davis D, Tagliaferri M, Perez E. Change in topoisomerase 1 (Top1) positive circulating tumor cells impacts overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol. **Clin Cancer Res** 2018 Jul 15;24(14):3348-3357.
- Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llargo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, **Cortes J**, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. **Nat Cell Biol**. 2018 Feb;20(2):211-221
- Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, **Cortes J**. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. **J Clin Oncol** 2018 Mar 20;36(9):884-890